NEW YORK–(BUSINESS WIRE)– Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the company
will present a corporate update at the Jefferies London Healthcare
Conference on Wednesday, November 16, 2016 at 8:00 a.m. GMT.
A live webcast of the presentation will be accessible through the
Investor Relations section of the company’s website at www.synergypharma.com.
A replay of the webcast will be available on Synergy’s website for 60
days following the conference.
About Synergy Pharmaceuticals Inc.
Synergy is a biopharmaceutical company focused on the development and
commercialization of novel gastrointestinal (GI) therapies. The company
has pioneered discovery, research and development efforts around analogs
of uroguanylin, a naturally occurring human GI peptide, for the
treatment of GI diseases and disorders. Synergy discovered, is
developing and controls 100% worldwide rights to its proprietary
uroguanylin analog platform that includes two lead product candidates –
plecanatide and dolcanatide. Plecanatide is Synergy’s first uroguanylin
analog currently being evaluated for use as a once-daily tablet for
chronic idiopathic constipation and irritable bowel syndrome with
constipation. Dolcanatide is Synergy’s second uroguanylin analog
currently being explored for ulcerative colitis. For more information,
please visit www.synergypharma.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161110005861/en/
Contacts
Synergy Pharmaceuticals Inc.
Gem Hopkins, 212-584-7610
VP,
Investor Relations and Corporate Communications
ghopkins@synergypharma.com
Source: Synergy Pharmaceuticals Inc.
Cet article Synergy Pharmaceuticals to Present at Jefferies 2016 London
Healthcare Conference est apparu en premier sur EEI-BIOTECHFINANCES.